New heart drug under watch in japan
NCT ID NCT07383025
Summary
This study is monitoring the real-world safety and effectiveness of the drug mavacamten in Japanese patients with obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and obstructs blood flow. It will enroll about 200 patients who are prescribed the drug as part of their normal care. The main goal is to track any side effects and see how well the drug works in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
CMIC Co., Ltd
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.